A THYROID analog has been sought with a potent cholesterol-lowering action and minimal metabolic effects that could be given to patients with coronary heart disease and angina pectoris. Di, tri, and tetraiodothyronine as well as numerous derivatives of these compounds have been studied.1-9 These substances lowered the level of the beta and other low-density lipoproteins but no dissociation of this effect from the concurrent increased metabolism was noted. Of all compounds tested, the D-isomers of thyroxine appeared to exert a disproportionate effect between cholesterol and general metabolic effects. 3 6,7, 10 This observation led to clinical trials with this agent. Starr and associates"1 reported that 16 mg. per day of sodium D-thyroxine caused no change in the basal metabolic rate. The serum cholesterol levels were significantly reduced in a group of patients with diabetes mellitus and idiopathic hypercholesteremia. In only one patient was angina increased. Oliver and Boyd12 13 noted good effects on lipids with Dthyroxine, but cautioned about the use of higher doses in patients with angina pectoris. Engleberg, '4 Soloff and Winters,'5 and Tuna'6 observed aggravation of heart disease in patients with coronary heart disease while receiving this drug. Jones and Cohen17 recommended that D-thyroxine be used only in patients free from cardiae symptoms.
In order to observe in as objective a way as possible whether there was a clinical dissociation between the serum lipid and cardiac effects of D-thyroxine, a double-blind study was carried out with patients known to have elevated serum cholesterol levels and angina pectoris. On the 4-mg. dose of D-thyroxine pulse rates were unchanged in six and slightly increased inl 10. The blood pressure of these patients was not significantly altered. Body weight was stationary in four, increased slightly in four, and dimrninished slightly in six. Thie two myxedemna patients lost 10 and 11 pounds, respectively, on 4 lng. daily for 3 months. No deterioration in the appearance of the electrocardiogram following the twostep test was observed in these patients.* However, the test had to be stopped prior to the elapse of the 3 minutes of exercise in 10 patients because of angina, wh ile they were receiving 4 mg. of D-thyroxine daily.
Discussion
In the present series of cases the aggravation of attacks of angina pectoris was more marked than has been previously reported."1-'7 Many of the patients recorded in the literature had hypercholestereniia without angina pectoris prior to starting the drug. The low iincidence of angina in this type of patient was understandable.
The trial with minimal amounts of D-thyroxine and stilbestrol was initiated with the hope of obtaining cholesterol lowering with little or no side effects of either drug. It was postulated that D-thyroxine might increase the turnover or possibly lower the miscible pool of cholesterol while estrogen shifted a portion of the cholesterol from the low-density to the high-density lipoproteins. Significant 
